细胞重编程：长寿科技的十亿美元级前沿领域

逆转生物衰老的探索已从单纯的症状管理转向一种全新的激进范式：细胞重编程。随着生物技术初创公司从理论研究转向人体临床试验，该行业正见证着前所未有的资本涌入，旨在倒转生物钟。

从端粒到细胞重编程

多年来，科学界一直专注于特定的“衰老标志”，例如端粒磨损和细胞衰老。端粒研究——针对染色体末端的保护性 DNA 帽——曾是行业标准，BioViva 首席执行官 Liz Parrish 利用基因疗法进行的自我实验便是其中的典型案例。同样，衰老细胞清除药物（senolytic drugs）旨在清除导致全身性炎症的“僵尸细胞”。

然而，研究重心已转向重编程。这种方法基于诺贝尔奖研究成果，该研究证明了四个特定的遗传因子可以将成年细胞转变为多能干细胞。与以往仅能减缓损伤的方法不同，重编程旨在让细胞回归年轻状态，从而有可能恢复组织功能、视力和认知能力。

高风险试验与临床里程碑

从小鼠模型向人体受试者的过渡标志着该行业的关键转折点。由哈佛大学生物学家 David Sinclair 共同创立的 Life Biosciences 最近在青光眼试验中为首位人体志愿者进行了给药。通过将实验性疗法直接注射到眼中，该公司旨在再生健康的神经，Sinclair 希望这一概念验证最终能扩展到全身回春。

Sinclair 还在关注 XPrize 基金会高达 1.01 亿美元的竞赛，他打算在其中测试一种“高度机密”的口服重编程药物。这些试验代表了首次现实世界的测试，即在小鼠身上看到的再生成功案例，是否可以在人类复杂的生物环境中安全地复制。

十亿美元级的回春竞赛

重编程的技术前景引发了全球最富有的投资者大量“干粉”（dry powder）的涌入。这种资本规模在生物技术领域是前所未有的：

• Altos Labs: Backed by Yuri Milner, Jeff Bezos, and others, this company launched with a staggering $3 billion to pursue cellular reprogramming.
• Retro Biosciences: Supported by $180 million from OpenAI’s Sam Altman, the company recently reached a $1.8 billion valuation with the goal of adding 10 healthy years to the human lifespan.
• NewLimit: Having raised $435 million, this billionaire-backed startup plans to begin human trials next year for a drug designed to rejuvenate the liver.
• Life Biosciences: Recently secured $80 million to accelerate its research into age-related diseases.

Why This Matters for the Future of Biotech

The pivot toward reprogramming signifies a move toward "generative" medicine rather than "preventative" medicine. If successful, this technology could transform aging from an inevitable decline into a manageable, and perhaps reversible, biological state. While significant risks remain—including the potential for uncontrolled cell growth—the sheer volume of funding and the commencement of human trials suggest that the industry views reprogramming as the most viable path toward true longevity.

Key Takeaways

• Shift in Strategy: The biotech industry is moving away from targeting individual hallmarks like telomeres toward "reprogramming" cells to a younger state.
• Massive Capital Influx: Companies like Altos Labs and Retro Biosciences have secured billions in funding from tech giants and billionaires to pursue rejuvenation.
• Human Trials Commencing: Life Biosciences has moved into the clinical phase with its first human dose for glaucoma, marking a major milestone for the field.